Umut Elboga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Umut Elboga has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
Ertan Sahin
7 shared publications- Levent Kabasakal
Istanbul University-Cerrahpasa
7 shared publications - Nalan Alan Selçuk
Yeditepe University School of Medicine: Yeditepe Universitesi Tip Fakultesi
7 shared publications Cüneyt Türkmen
5 shared publicationsEbuzer Kalender
Department of Nuclear Medicine, Gaziantep University, Gaziantep, Turkey
5 shared publications- Enes Yerdes
Department of Nuclear Medicine, Gaziantep University Faculty of Medicine, Gaziantep
5 shared publications
Latest Publications
- 9 November 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
Postrenal Acute Kidney Injury After Forced Diuresis During 68Ga-PSMA PET/CT
For active surveillance assessment, 68 Ga-PSMA PET/CT was performed in a 73-year-old man with Gleason 3+3 prostate adenocarcinoma. PET/CT showed a markedly enlarged prostate indenting the bladder base, with focal midline activity suggestive of prostatic urethral urinary retention. Intravenous furosemide was administered before 120-minute delayed imaging, which showed complete resolution of the activity and excluded pathologic uptake. After discharge, he developed urinary urgency and incomplete emptying, progressing to lower abdominal and pelvic pain with elevated creatinine. Postrenal acute kidney injury from acute urinary retention was diagnosed. Catheterization and inpatient monitoring normalized renal function, highlighting an underrecognized risk of forced diuresis.
- 9 November 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
Postrenal Acute Kidney Injury After Forced Diuresis During 68Ga-PSMA PET/CT
For active surveillance assessment, 68 Ga-PSMA PET/CT was performed in a 73-year-old man with Gleason 3+3 prostate adenocarcinoma. PET/CT showed a markedly enlarged prostate indenting the bladder base, with focal midline activity suggestive of prostatic urethral urinary retention. Intravenous furosemide was administered before 120-minute delayed imaging, which showed complete resolution of the activity and excluded pathologic uptake. After discharge, he developed urinary urgency and incomplete emptying, progressing to lower abdominal and pelvic pain with elevated creatinine. Postrenal acute kidney injury from acute urinary retention was diagnosed. Catheterization and inpatient monitoring normalized renal function, highlighting an underrecognized risk of forced diuresis.
- 14 August 2026
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 99 (1187) , 2406-2414
Comparison of 68Ga-FAPI PET/CT and 18F-FDG PET/CT in gastric cancer: impact on metastatic detection and stage migration
Objectives: To compare the diagnostic performance of 18F-fluorodeoxyglucose (18F-FDG) PET/CT and ⁶⁸Ga-FAPI PET/CT in patients with gastric cancer, with particular emphasis on metastatic detection and stage migration. Methods: Fifty-two patients with histopathologically confirmed gastric cancer who underwent both 18F-FDG PET/CT and ⁶⁸Ga-FAPI PET/CT were retrospectively analyzed. Primary tumor uptake, metastatic involvement, and tumor staging were evaluated for each modality. Detection rates for lymph node, peritoneal, liver, and bone metastases were compared. Diagnostic performance and stage migration between modalities were assessed. Quantitative parameters including standardized uptake value and tumor-to-background ratio were analyzed. Results: ⁶⁸Ga-FAPI PET/CT demonstrated significantly higher uptake in primary tumors compared with 18F-FDG PET/CT (P < .001). Peritoneal metastases were detected in 30.8% (16/52) of patients on ⁶⁸Ga-FAPI PET/CT compared with 13.5% (7/52) on 18F-FDG PET/CT (P = .004). Nodal metastases were also identified more frequently with ⁶⁸Ga-FAPI PET/CT. Both modalities showed high diagnostic performance for liver metastases, while ⁶⁸Ga-FAPI PET/CT demonstrated slightly higher sensitivity for bone lesions and 18F-FDG PET/CT showed slightly higher specificity. Overall stage migration between the 2 modalities occurred in 25.0% (13/52) of patients, predominantly due to upstaging associated with newly detected metastatic disease. In subgroup analysis, 18F-FDG uptake tended to be lower in signet-ring cell carcinoma, whereas FAPI uptake appeared less influenced by histological subtype. Conclusion: : ⁶⁸Ga-FAPI PET/CT improves detection of metastatic disease, particularly peritoneal involvement, compared with 18F-FDG PET/CT in patients with gastric cancer and may contribute to more accurate disease staging. Advances in knowledge: This study highlights the added value of 68Ga-FAPI PET/CT in identifying metastatic disease and altering clinical staging, particularly through improved detection of peritoneal involvement, which may impact treatment decision-making.
- 14 August 2026
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 99 (1187) , 2406-2414
Comparison of 68Ga-FAPI PET/CT and 18F-FDG PET/CT in gastric cancer: impact on metastatic detection and stage migration
Objectives: To compare the diagnostic performance of 18F-fluorodeoxyglucose (18F-FDG) PET/CT and ⁶⁸Ga-FAPI PET/CT in patients with gastric cancer, with particular emphasis on metastatic detection and stage migration. Methods: Fifty-two patients with histopathologically confirmed gastric cancer who underwent both 18F-FDG PET/CT and ⁶⁸Ga-FAPI PET/CT were retrospectively analyzed. Primary tumor uptake, metastatic involvement, and tumor staging were evaluated for each modality. Detection rates for lymph node, peritoneal, liver, and bone metastases were compared. Diagnostic performance and stage migration between modalities were assessed. Quantitative parameters including standardized uptake value and tumor-to-background ratio were analyzed. Results: ⁶⁸Ga-FAPI PET/CT demonstrated significantly higher uptake in primary tumors compared with 18F-FDG PET/CT (P < .001). Peritoneal metastases were detected in 30.8% (16/52) of patients on ⁶⁸Ga-FAPI PET/CT compared with 13.5% (7/52) on 18F-FDG PET/CT (P = .004). Nodal metastases were also identified more frequently with ⁶⁸Ga-FAPI PET/CT. Both modalities showed high diagnostic performance for liver metastases, while ⁶⁸Ga-FAPI PET/CT demonstrated slightly higher sensitivity for bone lesions and 18F-FDG PET/CT showed slightly higher specificity. Overall stage migration between the 2 modalities occurred in 25.0% (13/52) of patients, predominantly due to upstaging associated with newly detected metastatic disease. In subgroup analysis, 18F-FDG uptake tended to be lower in signet-ring cell carcinoma, whereas FAPI uptake appeared less influenced by histological subtype. Conclusion: : ⁶⁸Ga-FAPI PET/CT improves detection of metastatic disease, particularly peritoneal involvement, compared with 18F-FDG PET/CT in patients with gastric cancer and may contribute to more accurate disease staging. Advances in knowledge: This study highlights the added value of 68Ga-FAPI PET/CT in identifying metastatic disease and altering clinical staging, particularly through improved detection of peritoneal involvement, which may impact treatment decision-making.
- 12 August 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
Multiple Radioiodine-avid Skin Metastases From Thyroid Carcinoma Detected on Posttherapy 131I SPECT/CT
A 77-year-old man with papillary thyroid carcinoma had received radioactive iodine therapy for metastatic disease 8 years earlier and subsequently achieved remission. He represented with rising serum thyroglobulin levels, and biopsy of newly detected cutaneous lesions confirmed metastatic disease. Posttherapy 131 I SPECT/CT after 200 mCi demonstrated multiple radioiodine-avid cutaneous metastases involving the scalp, left auricular region, anterior chest wall, and dorsal region. This case highlights an exceptionally uncommon presentation of extensive, multifocal, radioiodine-avid cutaneous metastases detected on post-therapy 131 I SPECT/CT after a long disease-free interval.
- 12 August 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
Multiple Radioiodine-avid Skin Metastases From Thyroid Carcinoma Detected on Posttherapy 131I SPECT/CT
A 77-year-old man with papillary thyroid carcinoma had received radioactive iodine therapy for metastatic disease 8 years earlier and subsequently achieved remission. He represented with rising serum thyroglobulin levels, and biopsy of newly detected cutaneous lesions confirmed metastatic disease. Posttherapy 131 I SPECT/CT after 200 mCi demonstrated multiple radioiodine-avid cutaneous metastases involving the scalp, left auricular region, anterior chest wall, and dorsal region. This case highlights an exceptionally uncommon presentation of extensive, multifocal, radioiodine-avid cutaneous metastases detected on post-therapy 131 I SPECT/CT after a long disease-free interval.
- 10 August 2026
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 57 (1) , 181
Comparative Analysis of Lesion Detection and Uptake Characteristics of 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT in Gastric Cancer
- 10 August 2026
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 57 (1) , 181
Comparative Analysis of Lesion Detection and Uptake Characteristics of 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT in Gastric Cancer
- Open Access
- 16 June 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (11) , 6311-6327
Diagnostic Performance of ⁶⁸Ga-FAPI PET/CT, ¹⁸F-FDG PET/CT, and Breast MRI for Assessing Tumor Extent and Axillary Metastasis in Breast Cancer: A Histopathology-Referenced Retrospective Study
Purpose: To compare the diagnostic performance of ⁶⁸Ga-FAPI PET/CT, ¹⁸F-FDG PET/CT, and magnetic resonance imaging (MRI) in assessing primary tumor size, detecting additional intramammary foci, and identifying axillary lymph node metastasis (ALNM) in patients with invasive breast cancer (IBC) undergoing upfront surgery without neoadjuvant chemotherapy (NAC), using postoperative histopathology as the reference standard. Methods: This retrospective study included 60 IBC patients who underwent total mastectomy without NAC. All patients had preoperative ⁶⁸Ga-FAPI PET/CT, ¹⁸F-FDG PET/CT, and breast MRI. Primary tumor size, multifocality/multicentricity (MF/MC), and ALNM were evaluated for each modality. FAPI and FDG were additionally assessed for extra-axillary lymph nodes, internal mammary nodes, and distant metastases. Agreement between imaging- and pathology-based tumor size measurements, as well as the diagnostic performance for MF/MC and ALNM, were evaluated using correlation analyses and standard diagnostic accuracy metrics. Results: MRI (ρ = 0.866) and ⁶⁸Ga-FAPI PET/CT (ρ = 0.844) demonstrated the strongest correlation with pathologic tumor size, whereas ¹⁸F-FDG PET/CT showed lower agreement (ρ = 0.780). Breast MRI (45.0%) and ⁶⁸Ga-FAPI-PET/CT (38.3%) were significantly superior to ¹⁸F-FDG PET/CT (18.3%) in detecting multifocal or multicentric disease ( p < 0.001). For ALNM detection, breast MRI achieved the highest sensitivity (87.5%) but showed lower specificity (72.7%). In contrast, ⁶⁸Ga-FAPI PET/CT combined high sensitivity (81.2%) with perfect specificity (100.0%), outperforming ¹⁸F-FDG PET/CT, which demonstrated lower sensitivity (43.8%) despite high specificity (93.2%). Additionally, ⁶⁸Ga-FAPIPET/CT identified metastatic findings not detected by ¹⁸F-FDG PET/CT, including seven axillary lymph nodes (11.7%), 29 additional intramammary tumor foci (48.3%), and four distant metastases (6.7%). Conclusion: ⁶⁸Ga-FAPI PET/CT demonstrated higher diagnostic performance than ¹⁸F-FDG PET/CT and accuracy comparable to breast MRI for primary tumor size estimation and detection of multifocal or multicentric disease. FAPI-PET/CT also provided higher specificity than MRI for ALNM assessment and identified additional metastatic lesions not detected by FDG-PET/CT, supporting its potential role as a complementary modality to MRI and an alternative functional imaging technique in selected patients.
- 16 June 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (11) , 6311-6327
Open AccessDiagnostic Performance of ⁶⁸Ga-FAPI PET/CT, ¹⁸F-FDG PET/CT, and Breast MRI for Assessing Tumor Extent and Axillary Metastasis in Breast Cancer: A Histopathology-Referenced Retrospective Study
Purpose: To compare the diagnostic performance of ⁶⁸Ga-FAPI PET/CT, ¹⁸F-FDG PET/CT, and magnetic resonance imaging (MRI) in assessing primary tumor size, detecting additional intramammary foci, and identifying axillary lymph node metastasis (ALNM) in patients with invasive breast cancer (IBC) undergoing upfront surgery without neoadjuvant chemotherapy (NAC), using postoperative histopathology as the reference standard. Methods: This retrospective study included 60 IBC patients who underwent total mastectomy without NAC. All patients had preoperative ⁶⁸Ga-FAPI PET/CT, ¹⁸F-FDG PET/CT, and breast MRI. Primary tumor size, multifocality/multicentricity (MF/MC), and ALNM were evaluated for each modality. FAPI and FDG were additionally assessed for extra-axillary lymph nodes, internal mammary nodes, and distant metastases. Agreement between imaging- and pathology-based tumor size measurements, as well as the diagnostic performance for MF/MC and ALNM, were evaluated using correlation analyses and standard diagnostic accuracy metrics. Results: MRI (ρ = 0.866) and ⁶⁸Ga-FAPI PET/CT (ρ = 0.844) demonstrated the strongest correlation with pathologic tumor size, whereas ¹⁸F-FDG PET/CT showed lower agreement (ρ = 0.780). Breast MRI (45.0%) and ⁶⁸Ga-FAPI-PET/CT (38.3%) were significantly superior to ¹⁸F-FDG PET/CT (18.3%) in detecting multifocal or multicentric disease ( p < 0.001). For ALNM detection, breast MRI achieved the highest sensitivity (87.5%) but showed lower specificity (72.7%). In contrast, ⁶⁸Ga-FAPI PET/CT combined high sensitivity (81.2%) with perfect specificity (100.0%), outperforming ¹⁸F-FDG PET/CT, which demonstrated lower sensitivity (43.8%) despite high specificity (93.2%). Additionally, ⁶⁸Ga-FAPIPET/CT identified metastatic findings not detected by ¹⁸F-FDG PET/CT, including seven axillary lymph nodes (11.7%), 29 additional intramammary tumor foci (48.3%), and four distant metastases (6.7%). Conclusion: ⁶⁸Ga-FAPI PET/CT demonstrated higher diagnostic performance than ¹⁸F-FDG PET/CT and accuracy comparable to breast MRI for primary tumor size estimation and detection of multifocal or multicentric disease. FAPI-PET/CT also provided higher specificity than MRI for ALNM assessment and identified additional metastatic lesions not detected by FDG-PET/CT, supporting its potential role as a complementary modality to MRI and an alternative functional imaging technique in selected patients.
- Open Access
- 16 March 2026
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 35 (2) , 85-91
Diagnostic Value of 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT in Laryngeal Cancer Staging
Diagnostic Value of 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT in Laryngeal Cancer Staging - Molecular Imaging and Radionuclide Therapy
- 16 March 2026
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 35 (2) , 85-91
Open AccessDiagnostic Value of 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT in Laryngeal Cancer Staging
Diagnostic Value of 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT in Laryngeal Cancer Staging - Molecular Imaging and Radionuclide Therapy
- 9 December 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (5) , 3042-3055
Istanbul PSMA PET/CT criteria (IPPC): an imaging-based approach to patient selection for active surveillance
Purpose To develop and validate the Istanbul [68Ga]Ga-PSMA PET/CT Criteria (IPPC), a standardized imaging framework designed to identify clinically significant prostate cancer (csPCa) and improve selection of candidates for active surveillance (AS). Methods [68Ga]Ga-PSMA PET/CT scans and histopathology from 163 men with biopsy-proven International Society of Urological Pathology (ISUP) Grade Group (GG) 1–2 prostate cancer who underwent radical prostatectomy were retrospectively reviewed by a multidisciplinary panel of nuclear medicine physicians, radiologists, and urologists. Imaging characteristics—including uptake pattern, morphology, localization, and SUVmax—were iteratively analyzed to define three categories: IPPC-1 (indolent), IPPC-2 (indeterminate), and IPPC-3 (csPCa-suspected). Delayed pelvic acquisitions were used as the primary dataset to enhance lesion definition and interpretability. Reproducibility was evaluated in 56 GG1 patients using Cohen’s and Fleiss’ κ statistics. Correlations between PSA, SUVmax, and IPPC categories were assessed, and ROC curve analysis was performed to determine the optimal SUVmax threshold for csPCa detection. Results Pathological upgrading occurred in 40% of all cases (74% GG1, 20% GG2). Among 56 GG1 patients, upgrading was 76%. SUVmax and PSA were significantly higher in IPPC-3 than in IPPC-2 (SUVmax 16.3 vs. 6.5, p < 0.001; PSA 7.8 vs. 5.3 ng/mL, p < 0.05). ROC analysis yielded an AUC = 0.76 with an optimal SUVmax cut-off of 8.21 (sensitivity 55%, specificity 90%). All lesions with SUVmax ≥ 12.0 corresponded to csPCa. Interobserver agreement was substantial (κ ≈ 0.70–0.74) and intraobserver concordance strong (κ ≈ 0.80–0.90), confirming high reproducibility. Conclusion IPPC provides a reproducible, biologically grounded method that integrates SUVmax, morphology, and anatomical localization to non-invasively refine AS eligibility. By identifying patients at genuine risk for csPCa while minimizing unnecessary biopsies, IPPC may improve confidence and adherence in AS management. Prospective multicentre validation within the ongoing I-SELECT trial (NCT07168616) will determine its broader clinical applicability.
- 9 December 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (5) , 3042-3055
Istanbul PSMA PET/CT criteria (IPPC): an imaging-based approach to patient selection for active surveillance
Purpose To develop and validate the Istanbul [68Ga]Ga-PSMA PET/CT Criteria (IPPC), a standardized imaging framework designed to identify clinically significant prostate cancer (csPCa) and improve selection of candidates for active surveillance (AS). Methods [68Ga]Ga-PSMA PET/CT scans and histopathology from 163 men with biopsy-proven International Society of Urological Pathology (ISUP) Grade Group (GG) 1–2 prostate cancer who underwent radical prostatectomy were retrospectively reviewed by a multidisciplinary panel of nuclear medicine physicians, radiologists, and urologists. Imaging characteristics—including uptake pattern, morphology, localization, and SUVmax—were iteratively analyzed to define three categories: IPPC-1 (indolent), IPPC-2 (indeterminate), and IPPC-3 (csPCa-suspected). Delayed pelvic acquisitions were used as the primary dataset to enhance lesion definition and interpretability. Reproducibility was evaluated in 56 GG1 patients using Cohen’s and Fleiss’ κ statistics. Correlations between PSA, SUVmax, and IPPC categories were assessed, and ROC curve analysis was performed to determine the optimal SUVmax threshold for csPCa detection. Results Pathological upgrading occurred in 40% of all cases (74% GG1, 20% GG2). Among 56 GG1 patients, upgrading was 76%. SUVmax and PSA were significantly higher in IPPC-3 than in IPPC-2 (SUVmax 16.3 vs. 6.5, p < 0.001; PSA 7.8 vs. 5.3 ng/mL, p < 0.05). ROC analysis yielded an AUC = 0.76 with an optimal SUVmax cut-off of 8.21 (sensitivity 55%, specificity 90%). All lesions with SUVmax ≥ 12.0 corresponded to csPCa. Interobserver agreement was substantial (κ ≈ 0.70–0.74) and intraobserver concordance strong (κ ≈ 0.80–0.90), confirming high reproducibility. Conclusion IPPC provides a reproducible, biologically grounded method that integrates SUVmax, morphology, and anatomical localization to non-invasively refine AS eligibility. By identifying patients at genuine risk for csPCa while minimizing unnecessary biopsies, IPPC may improve confidence and adherence in AS management. Prospective multicentre validation within the ongoing I-SELECT trial (NCT07168616) will determine its broader clinical applicability.
- Open Access
- 24 February 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (3) , 569
Efficacy of 177Lu-PSMA-617 Therapy in mCRPC Patients with Liver Metastases: Insights into Survival Outcomes and Predictors of Response
Objectives: Metastatic castration-resistant prostate cancer (mCRPC) is associated with poor prognosis, particularly in cases of liver metastases. 177Lu-PSMA-617 (commercially known as Pluvicto) is an FDA-approved radioligand therapy for mCRPC patients. This study aimed to evaluate the efficacy of 177Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients with liver metastases, focusing on progression-free survival (PFS), overall survival (OS), and factors influencing treatment response. Materials and Methods: This retrospective study included mCRPC patients (n = 32) with liver metastases treated with Lu-PSMA-617. Patient data, including prostate-specific antigen (PSA) levels, liver SUVmax values, Lutetium-PSMA therapy cycles, and survival outcomes, were collected. Kaplan–Meier survival analysis was used to calculate PFS and OS, while regression analysis was employed to identify factors associated with treatment response. Results: The median PFS and OS were 6 and 9 months, respectively. Partial regression was observed in patients with significantly lower PSA levels (median: 90.0 ng/mL, range: 22–699 ng/mL, p = 0.001) and liver SUVmax values (median: 17.9, range: 8.3–57.0, p = 0.008). A higher number of Lutetium-PSMA cycles correlated with improved treatment response (p = 0.010) and reduced liver SUVmax values (p = 0.043). Conclusions: Lu-PSMA-617 therapy is effective in managing mCRPC with liver metastases. Increased intensity of therapy exposure, reflected by a higher number of treatment cycles, is associated with a greater biochemical response, as indicated by reduced PSA levels, thereby supporting the rationale for personalized treatment strategies. These findings support the use of Lu-PSMA-617 in mCRPC patients with liver metastases, warranting further prospective studies.
- 24 February 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (3) , 569
Open AccessEfficacy of 177Lu-PSMA-617 Therapy in mCRPC Patients with Liver Metastases: Insights into Survival Outcomes and Predictors of Response
Objectives: Metastatic castration-resistant prostate cancer (mCRPC) is associated with poor prognosis, particularly in cases of liver metastases. 177Lu-PSMA-617 (commercially known as Pluvicto) is an FDA-approved radioligand therapy for mCRPC patients. This study aimed to evaluate the efficacy of 177Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients with liver metastases, focusing on progression-free survival (PFS), overall survival (OS), and factors influencing treatment response. Materials and Methods: This retrospective study included mCRPC patients (n = 32) with liver metastases treated with Lu-PSMA-617. Patient data, including prostate-specific antigen (PSA) levels, liver SUVmax values, Lutetium-PSMA therapy cycles, and survival outcomes, were collected. Kaplan–Meier survival analysis was used to calculate PFS and OS, while regression analysis was employed to identify factors associated with treatment response. Results: The median PFS and OS were 6 and 9 months, respectively. Partial regression was observed in patients with significantly lower PSA levels (median: 90.0 ng/mL, range: 22–699 ng/mL, p = 0.001) and liver SUVmax values (median: 17.9, range: 8.3–57.0, p = 0.008). A higher number of Lutetium-PSMA cycles correlated with improved treatment response (p = 0.010) and reduced liver SUVmax values (p = 0.043). Conclusions: Lu-PSMA-617 therapy is effective in managing mCRPC with liver metastases. Increased intensity of therapy exposure, reflected by a higher number of treatment cycles, is associated with a greater biochemical response, as indicated by reduced PSA levels, thereby supporting the rationale for personalized treatment strategies. These findings support the use of Lu-PSMA-617 in mCRPC patients with liver metastases, warranting further prospective studies.
- Open Access
- 23 February 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (3) , 127
Evaluation of Adrenal Metastases in Prostate Cancer Patients with [68GA]GA-PSMA PET/CT Imaging
Objectives: This study aimed to evaluate the imaging and clinical characteristics of adrenal metastases detected by [68Ga]Ga-PSMA PET/CT in prostate cancer patients, with a focus on diagnostic accuracy and prognostic implications. Specifically, we examined the correlation between adrenal lesion characteristics and prognostic markers, such as prostate-specific antigen (PSA) levels and Gleason scores. This study also assessed the diagnostic performance of PSA, standardized uptake value maximum (SUVmax), and Hounsfield Unit (HU) values in differentiating adrenal metastases from benign adrenal adenomas. Materials and Methods: This retrospective study included 44 prostate cancer patients with adrenal lesions identified using [68Ga]Ga-PSMA PET/CT between January 2020 and October 2024. The patients were categorized into two groups: benign adrenal adenomas (n = 16) and adrenal metastases (n = 28). The PET/CT imaging was performed using a 5-ring Discovery IQ PET/CT scanner with QClear reconstruction, following the injection of 2.5 MBq/kg [68Ga]Ga-PSMA ligand and a standardized uptake time of 60 min. The imaging parameters (SUVmax and HU values), clinical characteristics (PSA levels, Gleason scores, and presence of lymphadenopathy), and patient outcomes were analyzed. A ROC analysis was conducted to evaluate the diagnostic performance of these key parameters. Results: Patients with adrenal metastases had significantly higher PSA levels (mean: 45.6 ± 12.4 ng/mL vs. 18.3 ± 6.7 ng/mL; p < 0.01) and Gleason scores (median: 8 vs. 6; p < 0.01) than those with benign adenomas. SUVmax values were significantly elevated in metastatic lesions (mean: 12.8 ± 4.3 vs. 3.4 ± 1.2; p < 0.001), and HU values were also higher (mean: 45 ± 15 vs. 18 ± 10; p < 0.01). The ROC analysis revealed that SUVmax had the highest diagnostic accuracy (AUC: 0.87), followed by PSA (AUC: 0.85) and HU (AUC: 0.80). Disease progression was observed in 67.9% of metastatic cases versus 18.8% in the adenoma group (p < 0.001), and median overall survival was shorter in metastatic cases (24 months vs. 38 months; p < 0.01). Conclusions: [68Ga]Ga-PSMA PET/CT is a valuable imaging modality for distinguishing adrenal metastases from benign adenomas in prostate cancer patients. The integration of PSA, SUVmax, and HU values into diagnostic workflows enhances diagnostic precision and improves clinical decision-making. Future research should focus on the prospective validation of these findings in larger cohorts and explore artificial intelligence-based approaches for automated lesion characterization.
- 23 February 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (3) , 127
Open AccessEvaluation of Adrenal Metastases in Prostate Cancer Patients with [68GA]GA-PSMA PET/CT Imaging
Objectives: This study aimed to evaluate the imaging and clinical characteristics of adrenal metastases detected by [68Ga]Ga-PSMA PET/CT in prostate cancer patients, with a focus on diagnostic accuracy and prognostic implications. Specifically, we examined the correlation between adrenal lesion characteristics and prognostic markers, such as prostate-specific antigen (PSA) levels and Gleason scores. This study also assessed the diagnostic performance of PSA, standardized uptake value maximum (SUVmax), and Hounsfield Unit (HU) values in differentiating adrenal metastases from benign adrenal adenomas. Materials and Methods: This retrospective study included 44 prostate cancer patients with adrenal lesions identified using [68Ga]Ga-PSMA PET/CT between January 2020 and October 2024. The patients were categorized into two groups: benign adrenal adenomas (n = 16) and adrenal metastases (n = 28). The PET/CT imaging was performed using a 5-ring Discovery IQ PET/CT scanner with QClear reconstruction, following the injection of 2.5 MBq/kg [68Ga]Ga-PSMA ligand and a standardized uptake time of 60 min. The imaging parameters (SUVmax and HU values), clinical characteristics (PSA levels, Gleason scores, and presence of lymphadenopathy), and patient outcomes were analyzed. A ROC analysis was conducted to evaluate the diagnostic performance of these key parameters. Results: Patients with adrenal metastases had significantly higher PSA levels (mean: 45.6 ± 12.4 ng/mL vs. 18.3 ± 6.7 ng/mL; p < 0.01) and Gleason scores (median: 8 vs. 6; p < 0.01) than those with benign adenomas. SUVmax values were significantly elevated in metastatic lesions (mean: 12.8 ± 4.3 vs. 3.4 ± 1.2; p < 0.001), and HU values were also higher (mean: 45 ± 15 vs. 18 ± 10; p < 0.01). The ROC analysis revealed that SUVmax had the highest diagnostic accuracy (AUC: 0.87), followed by PSA (AUC: 0.85) and HU (AUC: 0.80). Disease progression was observed in 67.9% of metastatic cases versus 18.8% in the adenoma group (p < 0.001), and median overall survival was shorter in metastatic cases (24 months vs. 38 months; p < 0.01). Conclusions: [68Ga]Ga-PSMA PET/CT is a valuable imaging modality for distinguishing adrenal metastases from benign adenomas in prostate cancer patients. The integration of PSA, SUVmax, and HU values into diagnostic workflows enhances diagnostic precision and improves clinical decision-making. Future research should focus on the prospective validation of these findings in larger cohorts and explore artificial intelligence-based approaches for automated lesion characterization.